Alnylam reported early clinical findings for brezosiran, an investigational RNA medicine for Huntington’s disease, indicating dose-dependent reductions in mutant huntingtin in cerebrospinal fluid. In the company’s update shared at the European Huntington’s Disease Network Clinical Research Congress, Alnylam said patients receiving the highest dose saw average mutant huntingtin levels fall by about 60% to 64% depending on assay. Alnylam described the safety profile as “encouraging” and said it plans to start a placebo-controlled study next year to assess whether brezosiran can slow disease progression. The company’s positioning centers on achieving meaningful target engagement in the central nervous system while moving toward outcomes trials. The immediate industry implication is that RNA silencing approaches in neurodegeneration are continuing to generate biomarker signals, with the next critical step being whether knockdown translates into clinical benefit. For biotech planners, the reported biomarker magnitude sets an expectation for the design and endpoints of the forthcoming controlled study. The story also highlights the ongoing challenge for Huntington programs: early efficacy signals must survive the transition from biomarker improvement to patient-relevant slowing of neurodegenerative decline.